We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Labeling of Ready-to-Use Prescription Drug Injectables Subject of FDA Guidance
Labeling of Ready-to-Use Prescription Drug Injectables Subject of FDA Guidance
Recommendations on labeling of injectable prescription drug product information submitted in an NDA or certain BLAs is the subject of an FDA guidance on dose banding.